Aberrant activation of AKT has been shown to occur frequently in human cancers4,5, including colorectal cancer6, liver cancer, etc.7,8 Currently, AKT has been the subject of intense research into PI3 kinase transduction signaling, and has become a hot target for cancer treatment, stroke treatment and diabetes drugs7–9. The gene discussed is AKT1; the disease is liver cancer.